Pro Medicus (ASX:PME) has been upgraded by Barrenjoey to "overweight" after a 40% decline from its February peak, Australian Financial Review reported Tuesday citing Josh Kannourakis from the research firm.
The research firm maintained Pro Medicus' price target of AU$275, the report said.
The analyst said he now considers the company "undervalued" but its valuations continue to be a "key debate".
He added that a recent rollout of its core platform for medical imaging technology with an unnamed customer has "proven the company's competitive advantage," as cited in the report.
(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.